Appellate Court Rules FDA Cannot Regulate Tobacco Products

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 9
Volume 7
Issue 9

WASHINGTON--A Federal appeals court has ruled that regulation of tobacco rests with Congress, not the FDA. In a 2-to-1 vote, a panel of the Fourth Circuit Court of Appeals, Richmond, Va, overturned a lower court ruling that had upheld FDA’s right to regulate tobacco.

WASHINGTON--A Federal appeals court has ruled that regulation of tobacco rests with Congress, not the FDA. In a 2-to-1 vote, a panel of the Fourth Circuit Court of Appeals, Richmond, Va, overturned a lower court ruling that had upheld FDA’s right to regulate tobacco.

The judges wrote, in the majority opinion: "We do not dispute in this case that Congress has charged the FDA with protecting the public health and that tobacco products present serious health risks for the public."

However, the judges went on to say, there is "strong evidence that Congress has reserved for itself the regulation of tobacco products rather than delegating that regulation to the FDA. . . . Based on our review of the record, the FDA lacks jurisdiction to regulate tobacco products, and all of the FDA’s regulations of tobacco products are invalid."

The proposed comprehensive tobacco bill, defeated in the Senate in June, would have explicitly granted FDA the right to regulate nicotine as a drug and cigarettes as a drug-delivery system.

The appellate court ruling overturns the FDA’s program to restrict teenage tobacco use that included requiring persons under age 27 to present photo ID when purchasing cigarettes and prohibiting the sale of tobacco products to persons under the age of 18.

Justice Department officials plan to appeal the ruling to the full Fourth Circuit appellate court. If the full court does not overturn the ruling of the three-judge panel, the government could then take its appeal to the US Supreme Court. The FDA’s antitobacco regulations will remain in effect during the appeals.

Related Videos
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.